Advances in Nanomedicine Strategies to Target Tumor-associated Macrophage

doi:10.13701/j.cnki.kqyxyj.2019.06.001

Abstract

Abstract: Tumor associated macrophage (TAM), one of the most important immune cells in tumor microenvironment, plays an important part in the occurrence and development of tumor. TAM-targeted immunotherapy is the frontier and hotspot of tumor therapy. Due to its excellent physical and chemical properties, nano-drug delivery system provides a new idea and direction for targeted regulation of TAM. In this paper, the current situation of targeted regulation of TAM by nanomaterials to kill tumor cells is reviewed.

Key words: Tumor associated macrophage, Target therapy, Nanomaterials

SUN Hong-chen, LI Xing. Advances in Nanomedicine Strategies to Target Tumor-associated Macrophage[J]. Journal of Oral Science Research, 2019, 35(6): 511-516.

References

[1] Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets [J]. Nat Rev Immunol, 2011, 11(11):723-737.
[2] Noman MZ, Desantis G, Janji B, et al. PD-L1 is a novel direct target of HIF-1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation [J]. J Exp Med, 2014, 211(5):781-790.
[3] Karagiannis GS, Pastoriza JM, Wang Y, et al. Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism [J]. Sci Transl Med, 2017, 9(397),pii: eaan0026.
[4] Du R, Lu KV, Petritsch C, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion [J]. Cancer Cell, 2008, 13(3):206-220.
[5] Wyckoff J, Wang W, Lin EY, et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors [J]. Cancer Res, 2004, 64(19):7022-7029.
[6] Segall JE, Condeelis J. Intravital imaging of cell movement in tumours [J]. Nat Rev Cancer, 2003, 3(12):921-930.
[7] Casazza A, Laoui D, Wenes M, et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity [J]. Cancer Cell, 2013, 24(6):695-709.
[8] Guruvayoorappan C. Tumor versus tumor-associated macrophages: how hot is the link [J]. Integr Cancer Ther, 2008, 7(2):90-95.
[9] Gazzaniga S, Bravo AI, Guglielmotti A, et al. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft [J]. J Invest Dermatol, 2007, 127(8):2031-2041.
[10] Ahn GO, Tseng D, Liao CH, et al. Inhibition of Mac-1 (CD11b/CD18)enhances tumor response to radiation by reducing myeloid cell recruitment [J]. Proc Natl Acad Sci U S A, 2010, 107(18):8363-8368.
[11] Prada CE, Jousma E, Rizvi TA, et al. Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition [J]. Acta Neuropathol, 2013, 125(1):159-168.
[12] Pyonteck SM, Akkari L, Schuhmacher AJ, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression [J]. Nat Med, 2013, 19(10): 1264-1272.
[13] Ries CH, Cannarile MA, Hoves S, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy [J]. Cancer Cell, 2014, 25(6):846-859.
[14] Jensen JL, Rakhmilevich A, Heninger E, et al. Tumoricidal effects of macrophage-activating immunotherapy in a murine model of relapsed/refractory multiple myeloma [J]. Cancer Immunol Res, 2015, 3(80): 881-890.
[15] Yaddanapudi K, Putty K, Rendon BE, et al. Control of tumor-associated macrophage alternative activation by macrophage migration inhibitory factor [J]. J Immunol, 2013, 190(6):2984-2993.
[16] Binnemars-Postma K, Bansal R, Storm G, et al. Targeting the Stat6 pathway in tumor-associated macrophages reduces tumor growth and metastatic niche formation in breast cancer [J]. FASEB J, 2017, 32(2):969-978.
[17] Zhang W, Zhu XD, Sun HC, et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects [J]. Clin Cancer Res, 2010, 16(13):3420-3430.
[18] Alexis F, Pridgen E, Molnar LK, et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles [J]. Mol Pharm, 2008, 5(4):505-515.
[19] Nichols JW, Bae YH. EPR: Evidence and fallacy [J]. J Controlled Release, 2014, 190:451-464.
[20] Miller MA, Zheng YR, Gadde S, et al. Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug [J]. Nat Commun, 2015, 6:8692-8692.
[21] Shmeeda H, Amitay Y, Gorin J, et al. Co-encapsulation of alendronate and doxorubicin in pegylated liposomes: a novel formulation for chemo-immunotherapy of cancer [J]. J Drug Target, 2016, 24(9):1-29.
[22] Zou L, Tao Y, Payne G, et al. Targeted delivery of nano-PTX to the brain tumor-associated macrophages [J]. Oncotarget, 2017, 8(4): 6564-6578.
[23] Ernsting MJ, Hoang B, Lohse I, et al. Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle [J]. J Control Release Society, 2015, 206:122-130.
[24] Alizadeh D, Zhang L, Jungyeon-Hwang, et al. Tumor-associated macrophages are predominant carriers of cyclodextrin-based nanoparticles into gliomas [J]. Nanomedicine, 2010, 6(2):382-390.
[25] Bashir MR, Bhatti L, Marin D, et al. Emerging applications for ferumoxytol as a contrast agent in MRI [J]. J Magn Reson Imaging, 2015, 41(4):884-898.
[26] Zanganeh S, Hutter G, Spitler R, et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues [J]. Nat Nanotechnol, 2016, 11(11): 986-994.
[27] Rossi L, Serafini S, Antonelli A, et al. Macrophage depletion induced by clodronate-loaded erythrocytes [J]. J Drug Target, 2005, 13(2):99-111.
[28] Ozcan C, Otten MJ, Zaidi N. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation [J]. Nat Commun, 2014, 5(2):3065.
[29] Damascelli B. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients [J]. Transl Oncol, 2009, 2(2):59-64.
[30] Cullis J, Siolas D, Avanzi A, et al. Macropinocytosis of nab-paclitaxel drives macrophage activation in pancreatic cancer [J]. Cancer Immunol Res, 2017, 5(3): 182-190.
[31] Zhao D, Alizadeh D, Zhang L, et al. Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity [J]. Clin Cancer Res, 2011, 17(4):771-782.
[32] Zhou H, Zhao K, Li W, et al. The interactions between pristine graphene and macrophages and the production of cytokines/chemokines via TLR- and NF-κB-related signaling pathways [J]. Biomaterials, 2012, 33(29):6933-6942.
[33] Tao Y, Ju E, Ren J, et al. Immunostimulatory oligonucleotides-loaded cationic graphene oxide with photothermally enhanced immunogenicity for photothermal/immune cancer therapy [J]. Biomaterials, 2014, 35(37):9963-9971.
[34] Ma J, Liu R, Wang X, et al. A crucial role of lateral size for graphene oxide in activating macrophages and stimulating pro-inflammatory responses in cells and animals [J]. ACS Nano, 2015, 9(10):10498-10515.
[35] Hattori Y, Kawakami S, Suzuki S, et al. Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice [J]. Biochem Biophys Res Commun, 2004, 317(4):992-999.
[36] Locke LW, Mayo MW, Yoo AD, et al. PET imaging of tumor associated macrophages using mannose coated ⁶⁴Cu liposomes [J]. Biomaterials, 2012, 33(31):7785-7793.
[37] Niu M, Valdes S, Naguib YW, et al. Tumor-associated macrophage-mediated targeted therapy of triple-negative breast cancer [J]. Mol Pharm, 2016, 13(6):1833-1842.
[38] Ortega RA, Whitney B, Kavya S, et al. Manipulating the NF-κB pathway in macrophages using mannosylated, siRNA-delivering nanoparticles can induce immunostimulatory and tumor cytotoxic functions [J]. Int J Nanomedicine, 2016, 11:2163-2177.
[39] Turk MJ, Waters DJ, Low PS. Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma [J]. Cancer Lett, 2004, 213(2):0-172.
[40] Nagai T, Furusho Y, Li H, et al. Production of a high-affinity monoclonal antibody reactive with folate receptors alpha and beta [J]. Monoclon Antib Immunodiagn Immunother, 2015, 34(3):181-190.
[41] Daldrup-Link HE, Golovko D, Ruffell B, et al. MRI of tumor-associated macrophages with clinically applicable Iron oxide nanoparticles [J]. Clin Cancer Res, 2011, 17(17):5695-5704.
[42] Luo Y, Zhou H, Krueger J, et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer [J]. J Clin Invest, 2006, 116(8):2132-2141.
[43] Zhang X, Tian W, Cai X, et al. Hydrazinocurcumin encapsuled nanoparticles “re-educate” tumor-associated acrophages and exhibit anti-tumor effects on breast cancer collowing STAT3 suppression [J]. PLoS One, 2013, 8(6):e65896.
[44] Song X, Wan Z, Chen T, et al. Development of a multi-target peptide for potentiating chemotherapy by modulating tumor microenvironment [J]. Biomaterials, 2016, 108:44-56.
[45] Cook J, Hagemann T. Tumour-associated macrophages and cancer [J]. Curr Opin Pharmacol, 2013, 13(4):595-601.